Aprotinin (inhaled) — Competitive Intelligence Brief

Aprotinin (inhaled) (Aprotinin (inhaled)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serine protease inhibitor. Area: Pulmonary/Respiratory.

phase 3 Serine protease inhibitor Kallikrein, plasmin, trypsin, and other serine proteases Pulmonary/Respiratory Small molecule

Target snapshot

Aprotinin (inhaled) (Aprotinin (inhaled)) — Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion. Aprotinin is a serine protease inhibitor that blocks multiple coagulation and fibrinolytic enzymes to reduce bleeding and inflammation in the lungs.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aprotinin (inhaled) TARGET	Aprotinin (inhaled)	Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion	phase 3	Serine protease inhibitor	Kallikrein, plasmin, trypsin, and other serine proteases
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway
Low-volume C1-esterase inhibitor	Low-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase inhibitor (C1-INH protein)
Camostat mesylate	Camostat mesylate	Seoul National University Hospital	phase 3	Serine protease inhibitor	TMPRSS2 (Transmembrane Protease Serine 2)
C1 esterase inhibitor [human] liquid	C1 esterase inhibitor [human] liquid	Shire	phase 3	Serine protease inhibitor; plasma-derived protein replacement	C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serine protease inhibitor class)

1. Chong Kun Dang Pharmaceutical · 1 drug in this class
2. Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion · 1 drug in this class
3. Seoul National University Hospital · 1 drug in this class